666 results on '"Allemann P"'
Search Results
2. Inconclusiveness of psychometric testing of medication adherence questionnaires
- Author
-
Arnet, Isabelle, Eickhoff, Christiane, Sahm, Laura J, Caloz, Sabine, Mittag, Michael, Schulz, Martin, and Allemann, Samuel S
- Published
- 2024
- Full Text
- View/download PDF
3. Rapid biodegradation of microplastics generated from bio-based thermoplastic polyurethane.
- Author
-
Allemann, Marco, Tessman, Marissa, Reindel, Jaysen, Scofield, Gordon, Evans, Payton, Pomeroy, Robert, Burkart, Michael, Mayfield, Stephen, and Simkovsky, Ryan
- Subjects
Plastics ,Polyurethanes ,Microplastics ,Ecosystem ,Biodegradation ,Environmental - Abstract
The accumulation of microplastics in various ecosystems has now been well documented and recent evidence suggests detrimental effects on various biological processes due to this pollution. Accumulation of microplastics in the natural environment is ultimately due to the chemical nature of widely used petroleum-based plastic polymers, which typically are inaccessible to biological processing. One way to mitigate this crisis is adoption of plastics that biodegrade if released into natural environments. In this work, we generated microplastic particles from a bio-based, biodegradable thermoplastic polyurethane (TPU-FC1) and demonstrated their rapid biodegradation via direct visualization and respirometry. Furthermore, we isolated multiple bacterial strains capable of using TPU-FC1 as a sole carbon source and characterized their depolymerization products. To visualize biodegradation of TPU materials as real-world products, we generated TPU-coated cotton fabric and an injection molded phone case and documented biodegradation by direct visualization and scanning electron microscopy (SEM), both of which indicated clear structural degradation of these materials and significant biofilm formation.
- Published
- 2024
4. Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients
- Author
-
Mantziari, Styliani, Farinha, Hugo Teixeira, Messier, Marguerite, Winiker, Michael, Allemann, Pierre, Ozsahin, Esat Mahmut, Demartines, Nicolas, Piessen, Guillaume, and Schäfer, Markus
- Published
- 2024
- Full Text
- View/download PDF
5. Distinct Cognitive Function Profiles Are Associated With a Higher Presurgery Symptom Burden in Patients With Breast Cancer
- Author
-
Allemann-Su, Yu-Yin, Vetter, Marcus, Koechlin, Helen, Conley, Yvette, Paul, Steven M, Cooper, Bruce A, Kober, Kord M, Levine, Jon D, Miaskowski, Christine, and Katapodi, Maria C
- Subjects
Health Services and Systems ,Nursing ,Health Sciences ,Breast Cancer ,Depression ,Aging ,Mental Health ,Cancer ,Brain Disorders ,Mental Illness ,Behavioral and Social Science ,Women's Health ,Pain Research ,Clinical Research ,Humans ,Female ,Breast Neoplasms ,Pain ,Fatigue ,Sleep Wake Disorders ,Cognition ,Breast cancer ,Cancer-related cognitive impairment ,Cognitive function ,Sleep disturbance ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology and carcinogenesis - Abstract
BackgroundCancer-related cognitive impairment (CRCI) is a common symptom in patients with breast cancer. In our previous study of 397 women with breast cancer, we identified 3 groups of patients with distinct CRCI profiles (ie, high, moderate, and low-moderate attentional function). Compared with the other 2 classes, the low-moderate class was younger, had more comorbidities, and with lower functional status.ObjectivesIn this study, we expand on this work and evaluate for differences among these latent classes in the severity of psychological (depression and anxiety) and physical (fatigue, decrements in energy, sleep disturbance, and pain) symptoms before surgery.MethodsCancer-related cognitive impairment was assessed using the Attentional Functional Index from before through 6 months after surgery. Lower Attentional Functional Index scores indicate higher levels of CRCI. Psychological and physical symptoms were assessed with valid instruments. Parametric and nonparametric tests were used to evaluate for differences in symptom severity scores among the latent classes.ResultsApproximately 60% of patients experienced CRCI (ie, moderate and low-moderate classes). Significant differences were found among the 3 classes in the severity of trait and state anxiety, depressive symptoms, fatigue, and sleep disturbance (ie, high < moderate < low-moderate). In addition, compared with the other 2 classes, the low-moderate class reported higher pain interference scores.ConclusionsThese findings suggest that women with clinically meaningful levels of persistent CRCI have a relatively high symptom burden before surgery.Implications for practiceClinicians need to routinely perform preoperative assessments of CRCI and associated symptoms and initiate therapeutic interventions.
- Published
- 2023
6. Chromatic vision and structural assessment in primary congenital glaucoma
- Author
-
Kato, Renata Tiemi, Rolim-de-Moura, Christiane, and Allemann, Norma
- Published
- 2024
- Full Text
- View/download PDF
7. Chromatic vision and structural assessment in primary congenital glaucoma
- Author
-
Renata Tiemi Kato, Christiane Rolim-de-Moura, and Norma Allemann
- Subjects
Medicine ,Science - Abstract
Abstract Primary congenital glaucoma is a rare disease that occurs in early birth and can lead to low vision. Evaluating affected children is challenging and there is a lack of studies regarding color vision in pediatric glaucoma patients. This cross-sectional study included 21 eyes of 13 children with primary congenital glaucoma who were assessed using the Farnsworth D-15 test to evaluate color vision discrimination and by spectral domain optical coherence tomography to measure retinal fiber layer thickness. Age, visual acuity, cup-to-disc ratio and spherical equivalent data were also collected. Global and sectional circumpapillary and macular retinal fiber layer thicknesses were measured and compared based on color vision test performance. Four eyes (19%) failed the color vision test with diffuse dyschromatopsia patterns. Only age showed statistical significance in color vision test performance. Global and sectional circumpapillary and macular retinal fiber layer thicknesses were similar between the color test outcomes dyschromatopsia and normal. While the color vision test could play a role in assessing children with primary congenital glaucoma, further studies are needed to correlate it with damage to retinal fiber layer thickness.
- Published
- 2024
- Full Text
- View/download PDF
8. Catabolism of β-5 linked aromatics by Novosphingobium aromaticivorans
- Author
-
Fletcher Metz, Abigail M. Olsen, Fachuang Lu, Kevin S. Myers, Marco N. Allemann, Joshua K. Michener, Daniel R. Noguera, and Timothy J. Donohue
- Subjects
enzymes ,ligninolysis ,genomics ,biotechnology ,aromatic compounds ,genetics ,Microbiology ,QR1-502 - Abstract
ABSTRACT Aromatic compounds are an important source of commodity chemicals traditionally produced from fossil fuels. Aromatics derived from plant lignin can potentially be converted into commodity chemicals through depolymerization followed by microbial funneling of monomers and low molecular weight oligomers. This study investigates the catabolism of the β-5 linked aromatic dimer dehydrodiconiferyl alcohol (DC-A) by the bacterium Novosphingobium aromaticivorans. We used genome-wide screens to identify candidate genes involved in DC-A catabolism. Subsequent in vivo and in vitro analyses of these candidate genes elucidated a catabolic pathway composed of four required gene products and several partially redundant dehydrogenases that convert DC-A to aromatic monomers that can be funneled into the central aromatic metabolic pathway of N. aromaticivorans. Specifically, a newly identified γ-formaldehyde lyase, PcfL, opens the phenylcoumaran ring to form a stilbene and formaldehyde. A lignostilbene dioxygenase, LsdD, then cleaves the stilbene to generate the aromatic monomers vanillin and 5-formylferulate (5-FF). We also showed that the aldehyde dehydrogenase FerD oxidizes 5-FF before it is decarboxylated by LigW, yielding ferulic acid. We found that some enzymes involved in the β-5 catabolism pathway can act on multiple substrates and that some steps in the pathway can be mediated by multiple enzymes, providing new insights into the robust flexibility of aromatic catabolism in N. aromaticivorans. A comparative genomic analysis predicted that the newly discovered β-5 aromatic catabolic pathway is common within the order Sphingomonadales.IMPORTANCEIn the transition to a circular bioeconomy, the plant polymer lignin holds promise as a renewable source of industrially important aromatic chemicals. However, since lignin contains aromatic subunits joined by various chemical linkages, producing single chemical products from this polymer can be challenging. One strategy to overcome this challenge is using microbes to funnel a mixture of lignin-derived aromatics into target chemical products. This approach requires strategies to cleave the major inter-unit linkages of lignin to release monomers for funneling into valuable products. In this study, we report newly discovered aspects of a pathway by which the Novosphingobium aromaticivorans DSM12444 catabolizes aromatics joined by the second most common inter-unit linkage in lignin, the β-5 linkage. This work advances our knowledge of aromatic catabolic pathways, laying the groundwork for future metabolic engineering of this and other microbes for optimized conversion of lignin into products.
- Published
- 2024
- Full Text
- View/download PDF
9. ASO Visual Abstract: Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients
- Author
-
Mantziari, Styliani, Teixeira Farinha, Hugo, Messier, Marguerite, Winiker, Michael, Allemann, Pierre, Ozsahin, Esat Mahmut, Demartines, Nicolas, Piessen, Guillaume, and Schäfer, Markus
- Published
- 2024
- Full Text
- View/download PDF
10. Pharmacogenetic testing and counselling in the community pharmacy: mixed-methods study of a new pharmacist-led service
- Author
-
Jeiziner, Chiara, Meyer zu Schwabedissen, Henriette E., Hersberger, Kurt E., and Allemann, Samuel S.
- Published
- 2023
- Full Text
- View/download PDF
11. Non-adherence and epileptic emergency—reasons and solutions
- Author
-
Arnet, Isabelle, Dietrich, Fine, Rüegg, Stephan, and Allemann, Samuel S.
- Published
- 2023
- Full Text
- View/download PDF
12. Impact of positive microscopic resection margins (R1) after gastrectomy in diffuse-type gastric cancer
- Author
-
Gaspar-Figueiredo, Sérgio, Allemann, Pierre, Borgstein, Alexander B. J., Joliat, Gaëtan-Romain, Luzuy-Guarnero, Valentine, Brunel, Christophe, Sempoux, Christine, Gisbertz, Suzanne Sarah, Demartines, Nicolas, van Berge Henegouwen, Mark Ivo, Schäfer, Markus, and Mantziari, Styliani
- Published
- 2023
- Full Text
- View/download PDF
13. Rapid biodegradation of microplastics generated from bio-based thermoplastic polyurethane
- Author
-
Marco N. Allemann, Marissa Tessman, Jaysen Reindel, Gordon B. Scofield, Payton Evans, Robert S. Pomeroy, Michael D. Burkart, Stephen P. Mayfield, and Ryan Simkovsky
- Subjects
Medicine ,Science - Abstract
Abstract The accumulation of microplastics in various ecosystems has now been well documented and recent evidence suggests detrimental effects on various biological processes due to this pollution. Accumulation of microplastics in the natural environment is ultimately due to the chemical nature of widely used petroleum-based plastic polymers, which typically are inaccessible to biological processing. One way to mitigate this crisis is adoption of plastics that biodegrade if released into natural environments. In this work, we generated microplastic particles from a bio-based, biodegradable thermoplastic polyurethane (TPU-FC1) and demonstrated their rapid biodegradation via direct visualization and respirometry. Furthermore, we isolated multiple bacterial strains capable of using TPU-FC1 as a sole carbon source and characterized their depolymerization products. To visualize biodegradation of TPU materials as real-world products, we generated TPU-coated cotton fabric and an injection molded phone case and documented biodegradation by direct visualization and scanning electron microscopy (SEM), both of which indicated clear structural degradation of these materials and significant biofilm formation.
- Published
- 2024
- Full Text
- View/download PDF
14. SCS Seminar on Flow Chemistry 2024
- Author
-
Agnieska Ladosz and Christophe Allemann
- Subjects
Chemistry ,QD1-999 - Published
- 2024
- Full Text
- View/download PDF
15. Characterization of spatial integrity with active and passive implants in a low-field magnetic resonance linear accelerator scanner
- Author
-
Bertrand Pouymayou, Yoel Perez-Haas, Florin Allemann, Ardan M. Saguner, Nicolaus Andratschke, Matthias Guckenberger, Stephanie Tanadini-Lang, and Lotte Wilke
- Subjects
Implants ,Distortion ,MR-Linac ,MR-guided radiotherapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and Purpose: Standard imaging protocols can guarantee the spatial integrity of magnetic resonance (MR) images utilized in radiotherapy. However, the presence of metallic implants can significantly compromise this integrity. Our proposed method aims at characterizing the geometric distortions induced by both passive and active implants commonly encountered in planning images obtained from a low-field 0.35 T MR-linear accelerator (LINAC). Materials and Methods: We designed a spatial integrity phantom defining 1276 control points and covering a field of view of 20x20x20 cm3. This phantom was scanned in a water tank with and without different implants used in hip and shoulder arthroplasty procedures as well as with active cardiac stimulators. The images were acquired with the clinical planning sequence (balanced steady-state free-precession, resolution 1.5x1.5x1.5 mm3). Spatial integrity was assessed by the Euclidian distance between the control point detected on the image and their theoretical locations. A first plane free of artefact (FPFA) was defined to evaluate the spatial integrity beyond the larger banding artefact. Results: In the region extending up to 20 mm from the largest banding artefacts, the tested passive and active implants could cause distortions up to 2 mm and 3 mm, respectively. Beyond this region the spatial integrity was recovered and the image could be considered as unaffected by the implants. Conclusions: We characterized the impact of common implants on a low field MR-LINAC planning sequence. These measurements could support the creation of extra margin while contouring organs at risk and target volumes in the vicinity of implants.
- Published
- 2024
- Full Text
- View/download PDF
16. Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction
- Author
-
Florine M. Wiss, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble, Thorsten Mikoteit, and Markus L. Lampert
- Subjects
therapeutic drug monitoring ,pharmacogenetic ,adverse drug reaction ,adherence ,clozapine ,CYP2D6 ,Psychiatry ,RC435-571 - Abstract
Suspected adverse drug reactions (ADRs) during treatment with clozapine often prompt therapeutic drug monitoring (TDM) in clinical practice. Currently, there is no official recommendation for pharmacogenetic (PGx) testing in the context of clozapine therapy. In this case report, we demonstrate and discuss the challenges of interpreting PGx and TDM results highlighting the possibilities and limitations of both analytical methods. A 36-year-old male patient with catatonic schizophrenia was treated with clozapine. He experienced multiple hospitalizations due to elevated creatine kinase (CK) levels (up to 9000 U/L, reference range: 30-200 U/L). With no other medical explanation found, physicians suspected clozapine-induced ADRs. However, plasma levels of clozapine were consistently low or subtherapeutic upon admission, prompting us to conduct a PGx analysis and retrospectively review the patient’s TDM data, progress notes, and discharge reports. We investigated two possible hypotheses to explain the symptoms despite low clozapine plasma levels: Hypothesis i. suggested the formation and accumulation of a reactive intermediate metabolite due to increased activity in cytochrome P450 3A5 and reduced activity in glutathione S-transferases 1, leading to myotoxicity. Hypothesis ii. proposed under-treatment with clozapine, resulting in ineffective clozapine levels, leading to a rebound effect with increased catatonic symptoms and CK levels. After considering both data sources (PGx and TDM), hypothesis ii. appeared more plausible. By comprehensively assessing all available TDM measurements and examining them in temporal correlation with the drug dose and clinical symptoms, we observed that CK levels normalized when clozapine plasma levels were raised to the therapeutic range. This was achieved through hospitalization and closely monitored clozapine intake. Therefore, we concluded that the symptoms were not an ADR due to altered clozapine metabolism but rather the result of under-treatment. Interpreting TDM and PGx results requires caution. Relying solely on isolated PGx or single TDM values can result in misinterpretation of drug reactions. We recommend considering the comprehensive patient history, including treatment, dosages, laboratory values, clinic visits, and medication adherence.
- Published
- 2024
- Full Text
- View/download PDF
17. Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars – a prospective survey before and after the COVID-19 pandemic
- Author
-
Kirstin Messner, Christiane Eickhoff, Martin Schulz, Samuel S. Allemann, and Isabelle Arnet
- Subjects
Biological ,Biosimilars ,Survey ,Community pharmacy ,Knowledge ,Attitudes ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Knowledge, attitudes and substitution laws of biosimilars are not consistent across countries. Biosimilar acceptance among patients and healthcare professionals may be suffering from gaps in knowledge and understanding about biosimilars and their regulatory approval process. Pharmacists' roles and responsibilities changed considerably during the COVID-19 pandemic. Thus, they might have gained new skills and self-confidence in counseling and substitution of biosimilars. Aims To examine and compare the knowledge, perceptions and information needs of German and Swiss pharmacists regarding original biologicals and biosimilars in 2020 and 2022. Methods We conducted an online survey among Swiss and German community pharmacies in February 2020 (before) and August 2022 (after the COVID-19 pandemic). Descriptive statistics were calculated and the Chi-Square test was used for comparisons among categorical variables. Results A total of 764 pharmacists took part in the survey (390 in 2020 and 374 in 2022) with comparable demographics. The frequency of dispensing biologicals remained similar between German and Swiss pharmacists in 2020 and 2022, but the Swiss dispensation of biosimilars increased significantly in 2022 compared to 2020. Concerning the understanding of the term biosimilars, knowledge remained moderate in both countries in both years. Participants were equally familiar with the term and most felt sufficiently informed. In both countries, substitution with a biosimilar showed the least confidence of all attitudes. A third of the participants indicated correct substitution rules in their country. In both years, around 85% of the participants were highly interested in additional training on this topic. Discussion/Conclusion The results indicate that similarities and differences between Germany and Switzerland regarding knowledge and attitudes towards biologicals and biosimilars remained unchanged before and after the COVID-19 pandemic. An influence of the pandemic is unlikely. There is still a clear lack of knowledge among community pharmacists on biosimilars, especially regarding the substitution rules. Due to a rising market with many benefits but also big challenges to overcome, the topic of biosimilars should receive more attention in the future. This requires additional training for pharmacists.
- Published
- 2023
- Full Text
- View/download PDF
18. Overcoming Barriers: Strategies for Implementing Pharmacist-Led Pharmacogenetic Services in Swiss Clinical Practice
- Author
-
Florine M. Wiss, Deborah Jakober, Markus L. Lampert, and Samuel S. Allemann
- Subjects
pharmacogenetics ,implementation ,CFIR ,ERIC ,pharmacist ,barrier ,Genetics ,QH426-470 - Abstract
There is growing evidence that pharmacogenetic analysis can improve drug therapy for individual patients. In Switzerland, pharmacists are legally authorized to initiate pharmacogenetic tests. However, pharmacogenetic tests are rarely conducted in Swiss pharmacies. Therefore, we aimed to identify implementation strategies that facilitate the integration of a pharmacist-led pharmacogenetic service into clinical practice. To achieve this, we conducted semi-structured interviews with pharmacists and physicians regarding the implementation process of a pharmacist-led pharmacogenetic service. We utilized the Consolidated Framework for Implementation Research (CFIR) to identify potential facilitators and barriers in the implementation process. Additionally, we employed Expert Recommendations for Implementing Change (ERIC) to identify strategies mentioned in the interviews and used the CFIR-ERIC matching tool to identify additional strategies. We obtained interview responses from nine pharmacists and nine physicians. From these responses, we identified 7 CFIR constructs as facilitators and 12 as barriers. Some of the most commonly mentioned barriers included unclear procedures, lack of cost coverage by health care insurance, insufficient pharmacogenetics knowledge, lack of interprofessional collaboration, communication with the patient, and inadequate e-health technologies. Additionally, we identified 23 implementation strategies mentioned by interviewees using ERIC and 45 potential strategies using the CFIR-ERIC matching tool. In summary, we found that significant barriers hinder the implementation process of this new service. We hope that by highlighting potential implementation strategies, we can advance the integration of a pharmacist-led pharmacogenetic service in Switzerland.
- Published
- 2024
- Full Text
- View/download PDF
19. Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars – a prospective survey before and after the COVID-19 pandemic
- Author
-
Messner, Kirstin, Eickhoff, Christiane, Schulz, Martin, Allemann, Samuel S., and Arnet, Isabelle
- Published
- 2023
- Full Text
- View/download PDF
20. Functional, biological, and radiological evaluation of the pancreaticojejunal anastomosis 1 year after pancreatoduodenectomy: a prospective study
- Author
-
Joliat, Gaëtan-Romain, Allemann, Pierre, Labgaa, Ismail, Demartines, Nicolas, Vietti Violi, Naik, Schmidt, Sabine, and Schäfer, Markus
- Published
- 2023
- Full Text
- View/download PDF
21. Up-scaling a Sol-Gel Process for the Production of a Multi-Component Xerogel Powder
- Author
-
Barbara Pföss, Jonathan Caldi, Sutida Jansod, Christophe Allemann, Pierre Brodard, and Roger Marti
- Subjects
Glass ceramic ,Sol-gel chemistry ,Up-scaling ,Chemistry ,QD1-999 - Abstract
A sol-gel process for the synthesis of a multi-component oxide material from the system SiO2-ZrO2-Al2O3underwent optimization and up-scaling. Initially, on a laboratory scale, components including precursors, catalysts, and additives were methodically evaluated to ensure a safe and efficient transition to larger volumes. Subsequently, the equipment for the whole setup of the sol-gel process was strategically selected. Leveraging insights from these optimizations, the process was successfully scaled-up to pilot-scale operation, conducting hydrolysis, condensation reactions, gelation, aging, and drying within a single, integrated conical dryer system for an 80 L batch. A visual test and FTIR spectroscopy were applied for process control and monitoring.
- Published
- 2024
- Full Text
- View/download PDF
22. Relationship between electronically monitored adherence to direct oral anticoagulants and ischemic or hemorrhagic events after an initial ischemic stroke-A case control study.
- Author
-
Katharina Rekk, Isabelle Arnet, Fine Dietrich, Alexandros A Polymeris, Philippe A Lyrer, Stefan T Engelter, Sabine Schaedelin, and Samuel S Allemann
- Subjects
Medicine ,Science - Abstract
BackgroundPatients with atrial fibrillation (AF) have a high risk for recurrent clinical events after an ischemic stroke. Direct oral anticoagulants (DOAC) are prescribed for secondary prevention. Adherence to DOAC is crucial mainly because of their short elimination half-life. Non-adherence to DOAC can negatively impact patients' outcomes. The relationship between (non-)adherence and recurrent clinical events is unknown in AF patients after initial stroke. We investigated adherence to DOAC in stroke survivors with AF who were included in the MAAESTRO study at the University Hospital Basel, Switzerland, between 2008 and 2022.MethodsThis study is a secondary analysis of data from MAAESTRO with a matched nested case-control design and 1:2 ratio. DOAC intake was measured with a small electronic device (Time4MedTM). We defined two arbitrary intervals of 17 days and 95 days as the longest time spans with electronic monitoring data per patient to maximize the number of participants with adequate amount of observation time available for analysis. Taking and timing adherence were calculated retrospectively i.e., prior to the recurrent event for cases. Trendline analysis of adherence over 95 days was calculated. Linear regression analysis was performed after adjusting for the co-variables age and daily pill burden. Sensitivity analysis was performed with controls for intervals in the reverse direction (prospectively).ResultsWe analyzed 11 cases and 22 matched controls (mean age: 75.9 ± 9.2 years vs. 73.1 ± 8.4 years; n.s.) with similar stroke characteristics (NIHSS, mRS, MoCA) and 36.4% women in each group. Mean adherence values were high and similar between cases and controls (95 days taking: 87.0 ± 18.9% (cases) vs. 90.8 ± 9.8% (controls), n.s.; similar values for timing adherence). Six hemorrhagic and five ischemic events had occurred. Compared to controls, a significantly higher 95 days taking adherence was observed for hemorrhagic events (96.0 ± 5.0% (cases) vs. 88.1 ± 11.5% (controls); pConclusionBecause recurrent ischemic events after an AF-related stroke were associated with low adherence to DOAC 96%.Trial registrationClinicalTrials.gov NCT03344146.
- Published
- 2024
- Full Text
- View/download PDF
23. Initiation of oral hepatitis C virus treatment: Which barriers are pertinent for ambulatory individuals with a history of illicit substance use? A qualitative interview study
- Author
-
Selina Barbati, Johannes Strasser, Samuel S. Allemann, and Isabelle Arnet
- Subjects
barriers ,direct‐acting antivirals ,hepatitis C ,people who inject drugs ,qualitative research ,Medicine - Abstract
Abstract Background and Aims The World Health Organization has set a goal to eradicate hepatitis C virus (HCV) by the year 2030. Nonadherence to HCV treatment has substantial economic implications due to high treatment costs, among others. Barriers to start HCV treatment may be critical. The aim of this study was to assess pertinent barriers to HCV treatment in ambulatory patients with a history of illicit substance use and to compare them to the literature. Methods Barriers to HCV treatment mentioned by the key risk group (i.e., people who inject drugs) were retrieved from literature through a pragmatic literature search. From 34 published articles, we identified 80 modifiable barriers that were bundled in 23 items within the four topics “Personal difficulties and barriers to treatment,” “Personal motivation to be treated,” “Knowledge about the disease,” and “Received information about the medicine.” In‐depth semistructured interviews were performed face‐to‐face with ambulatory patients from the University Psychiatric Clinics in Basel, Switzerland. Transcripts were coded inductively. Results Interviews were performed with seven individuals (mean age: 48.3 years; range: 38–63 years; one woman) treated with oral direct‐acting antivirals between 2014 and 2022. Thirteen barriers to start HCV treatment were mentioned that corresponded to the five categories: information, attitudes, swallowing difficulties, social environment, and unfavorable lifestyle. The barrier “swallowing difficulties” emerged exclusively from the statements provided by the interviewees. Conclusion Barriers to the initiation of HCV treatment indicated by our interviewees clearly differed from the literature. Notably, the challenge of swallowing medicines may be particularly relevant for physicians prescribing and pharmacists dispensing HCV medication.
- Published
- 2024
- Full Text
- View/download PDF
24. Clinical relevance and implementation into daily practice of pharmacist-prescribed medication for the management of minor ailments
- Author
-
Noelia Amador-Fernández, Irina Botnaru, Samuel Sebastian Allemann, Véronique Kälin, and Jérôme Berger
- Subjects
community pharmacies ,community pharmacy services ,triage ,autonomous pharmacist prescribing ,implementation science ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: Autonomous pharmacist prescribing was legally introduced in Switzerland in 2019 with the reclassification from prescription medication to pharmacist prescribing of 105 medications for sixteen indications. Its aim was to limit medical consultations and healthcare costs.Objectives: To evaluate the clinical relevance of the pharmacy prescribing medications compared to the over-the-counter medications (OTCs) and to evaluate its implementation into daily practice.Methods: A comparison was undertaken by clinical pharmacists to evaluate chemical and galenical equivalences between pharmacy prescribing medications and OTCs using compendium. ch and pharmavista. ch. Then, a scoping review was carried out in October 2021 to determine clinical relevance according to clinical guidelines’ recommendations. Clinical relevance was completed by determining if pharmacy prescribing medications were part of a homogeneous therapeutic class (no differences in efficacy and safety considered in clinical guidelines, but rather inter-molecular differences) that included an OTC medication. To identify the most clinically relevant pharmacy prescribing medications, first-line treatments were considered. The implementation into daily practice in Swiss community pharmacies was evaluated through an online questionnaire distributed via e-mail from the national pharmacists’ association and LinkedIn®. It included 15 questions divided in: pharmacy demographics, experience on pharmacy prescribing, use of prescribing medications and opinion about the them.Results: Of the 105 pharmacy prescribing medications, 20 (19.0%) were first-line treatments without OTC equivalences. Six of them were OTCs reclassified for safety reasons. Ten medications (9.5%) showed a negative clinical relevance (they were not first-line therapeutic options to support pharmacist when managing patients or considered as to be avoided) compared to the OTCs available. For the questionnaire, 283 pharmacists from the German (40.3%), French (37.1%) and Italian-speaking regions (16.9%) answered. In the previous 6 months, 41.7% pharmacies had delivered 10–50 medications and 30.0% between 1 and 10 medications. In situations where patients could be equally treated with a pharmacy prescribing medication or OTC (with an identical OTC, similar OTC or an OTC for the same therapeutic group): 75.6%, 74.9% and 84.8% of pharmacists, respectively, would have chosen OTCs because it required less documentation and it did not require patients’ payment for the service. In addition, pharmacists’ lack of training was also mentioned as barrier for providing the service.Conclusion: Most pharmacist prescribing medications do not present clinical advantages compared to OTCs. In addition, other barriers for implementation were also pharmacists’ training and patient medications costs.
- Published
- 2024
- Full Text
- View/download PDF
25. Pre-Surgery Demographic, Clinical, and Symptom Characteristics Associated with Different Self-Reported Cognitive Processes in Patients with Breast Cancer
- Author
-
Allemann-Su, Yu-Yin, Vetter, Marcus, Koechlin, Helen, Paul, Steven M, Cooper, Bruce A, Oppegaard, Kate, Melisko, Michelle, Levine, Jon D, Conley, Yvette, Miaskowski, Christine, and Katapodi, Maria C
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Behavioral and Social Science ,Depression ,Mental Health ,Brain Disorders ,Clinical Research ,Breast Cancer ,Cancer ,Mental health ,Good Health and Well Being ,breast cancer ,cancer-related cognitive impairment ,cognitive flexibility ,inhibitory control ,working memory ,Oncology and carcinogenesis - Abstract
Cancer related cognitive impairment (CRCI) is a common and persistent symptom in breast cancer patients. The Attentional Function Index (AFI) is a self-report measure that assesses CRCI. AFI includes three subscales, namely effective action, attentional lapses, and interpersonal effectiveness, that are based on working memory, inhibitory control, and cognitive flexibility. Previously, we identified three classes of patients with distinct CRCI profiles using the AFI total scores. The purpose of this study was to expand our previous work using latent class growth analysis (LCGA), to identify distinct cognitive profiles for each of the AFI subscales in the same sample (i.e., 397 women who were assessed seven times from prior to through to 6 months following breast cancer surgery). For each subscale, parametric and non-parametric statistics were used to determine differences in demographic, clinical, and pre-surgical psychological and physical symptoms among the subgroups. Three-, four-, and two-classes were identified for the effective action, attentional lapses, and interpersonal effectiveness subscales, respectively. Across all three subscales, lower functional status, higher levels of anxiety, depression, fatigue, and sleep disturbance, and worse decrements in energy were associated with worse cognitive performance. These and other modifiable characteristics may be potential targets for personalized interventions for CRCI.
- Published
- 2022
26. Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study
- Author
-
Bollinger A, Stäuble CK, Jeiziner C, Wiss FM, Hersberger KE, Lampert ML, Meyer zu Schwabedissen HE, and Allemann SS
- Subjects
pharmacogenomics ,pgx ,personalized medicine ,clinical pharmacy ,clinical practice ,medication review ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Anna Bollinger,1 Céline K Stäuble,1,2 Chiara Jeiziner,1 Florine M Wiss,1,2 Kurt E Hersberger,1 Markus L Lampert,1,2 Henriette E Meyer zu Schwabedissen,1 Samuel S Allemann1 1Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; 2Institute of Hospital Pharmacy, Solothurner Spitäler AG, Olten, SwitzerlandCorrespondence: Anna Bollinger, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, Basel, 4056, Switzerland, Tel +41 61 207 66 31, Email a.bollinger@unibas.chPurpose: Pharmacogenetics (PGx) is an emerging aspect of personalized medicine with the potential to increase efficacy and safety of pharmacotherapy. However, PGx testing is still not routinely integrated into clinical practice. We conducted an observational case series study where PGx information from a commercially available panel test covering 30 genes was integrated into medication reviews. The aim of the study was to identify the drugs that are most frequently object of drug-gene-interactions (DGI) in the study population.Patients and Methods: In out-patient and in-patient settings, we recruited 142 patients experiencing adverse drug reaction (ADR) and/or therapy failure (TF). Collected anonymized data from the individual patient was harmonized and transferred to a structured database.Results: The majority of the patients had a main diagnosis of a mental or behavioral disorder (ICD-10: F, 61%), of musculoskeletal system and connective tissue diseases (ICD-10: M, 21%), and of the circulatory system (ICD-10: I, 11%). The number of prescribed medicines reached a median of 7 per person, resulting in a majority of patients with polypharmacy (≥ 5 prescribed medicines, 65%). In total, 559 suspected DGI were identified in 142 patients. After genetic testing, an association with at least one genetic variation was confirmed for 324 suspected DGI (58%) caused by 64 different drugs and 21 different genes in 141 patients. After 6 months, PGx-based medication adjustments were recorded for 62% of the study population, whereby differences were identified in subgroups.Conclusion: The data analysis from this study provides valuable insights for the main focus of further research in the context of PGx. The results indicate that most of the selected patients in our sample represent suitable target groups for PGx panel testing in clinical practice, notably those taking drugs for mental or behavioral disorder, circulatory diseases, immunological diseases, pain-related diseases, and patients experiencing polypharmacy.Keywords: pharmacogenomics, PGx, personalized medicine, clinical pharmacy, clinical practice, medication review
- Published
- 2023
27. Drain Versus No Drain in Open Mesh Repair for Incisional Hernia, Results of a Prospective Randomized Controlled Trial
- Author
-
Willemin, Mélissa, Schaffer, Clara, Kefleyesus, Amaniel, Dayer, Anna, Demartines, Nicolas, Schäfer, Markus, and Allemann, Pierre
- Published
- 2023
- Full Text
- View/download PDF
28. Renal insufficiency and magnesium deficiency correlate with a decreased formation of biologically active cholecalciferol: a retrospective observational study
- Author
-
Rothen, Jean-Pierre, Rutishauser, Jonas, Arnet, Isabelle, and Allemann, Samuel S.
- Published
- 2023
- Full Text
- View/download PDF
29. Toward an Interdisciplinary Approach to Constructing Care Delivery Pathways From Electronic Health Care Databases to Support Integrated Care in Chronic Conditions: Systematic Review of Quantification and Visualization Methods
- Author
-
Luiza Siqueira do Prado, Samuel Allemann, Marie Viprey, Anne-Marie Schott, Dan Dediu, and Alexandra Lelia Dima
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundElectronic health care databases are increasingly used for informing clinical decision-making. In long-term care, linking and accessing information on health care delivered by different providers could improve coordination and health outcomes. Several methods for quantifying and visualizing this information into data-driven care delivery pathways (CDPs) have been proposed. To be integrated effectively and sustainably into routine care, these methods need to meet a range of prerequisites covering 3 broad domains: clinical, technological, and behavioral. Although advances have been made, development to date lacks a comprehensive interdisciplinary approach. As the field expands, it would benefit from developing common standards of development and reporting that integrate clinical, technological, and behavioral aspects. ObjectiveWe aimed to describe the content and development of long-term CDP quantification and visualization methods and to propose recommendations for future work. MethodsWe conducted a systematic review following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) recommendations. We searched peer-reviewed publications in English and reported the CDP methods by using the following data in the included studies: long-term care data and extracted data on clinical information and aims, technological development and characteristics, and user behaviors. The data are summarized in tables and presented narratively. ResultsOf the 2921 records identified, 14 studies were included, of which 13 (93%) were descriptive reports and 1 (7%) was a validation study. Clinical aims focused primarily on treatment decision-making (n=6, 43%) and care coordination (n=7, 50%). Technological development followed a similar process from scope definition to tool validation, with various levels of detail in reporting. User behaviors (n=3, 21%) referred to accessing CDPs, planning care, adjusting treatment, or supporting adherence. ConclusionsThe use of electronic health care databases for quantifying and visualizing CDPs in long-term care is an emerging field. Detailed and standardized reporting of clinical and technological aspects is needed. Early consideration of how CDPs would be used, validated, and implemented in clinical practice would likely facilitate further development and adoption. Trial RegistrationPROSPERO CRD42019140494; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=140494 International Registered Report Identifier (IRRID)RR2-10.1136/bmjopen-2019-033573
- Published
- 2023
- Full Text
- View/download PDF
30. Flow Chemistry Highlights
- Author
-
Agnieszka Ladosz and Christophe Allemann
- Subjects
Chemistry ,QD1-999 - Published
- 2023
- Full Text
- View/download PDF
31. Genetic Suppression of Lethal Mutations in Fatty Acid Biosynthesis Mediated by a Secondary Lipid Synthase
- Author
-
Allemann, Marco N and Allen, Eric E
- Subjects
Nutrition ,Genetics ,Human Genome ,Escherichia coli ,Fatty Acid Synthase ,Type II ,Fatty Acids ,Mutation ,Photobacterium ,deep sea ,lipids ,high pressure ,polyunsaturated fatty acid ,Microbiology - Abstract
The biosynthesis and incorporation of polyunsaturated fatty acids into phospholipid membranes are unique features of certain marine Gammaproteobacteria inhabiting high-pressure and/or low-temperature environments. In these bacteria, monounsaturated and saturated fatty acids are produced via the classical dissociated type II fatty acid synthase mechanism, while omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) are produced by a hybrid polyketide/fatty acid synthase-encoded by the pfa genes-also referred to as the secondary lipid synthase mechanism. In this work, phenotypes associated with partial or complete loss of monounsaturated biosynthesis are shown to be compensated for by severalfold increased production of polyunsaturated fatty acids in the model marine bacterium Photobacterium profundum SS9. One route to suppression of these phenotypes could be achieved by transposition of insertion sequences within or upstream of the fabD coding sequence, which encodes malonyl coenzyme A (malonyl-CoA) acyl carrier protein transacylase. Genetic experiments in this strain indicated that fabD is not an essential gene, yet mutations in fabD and pfaA are synthetically lethal. Based on these results, we speculated that the malonyl-CoA transacylase domain within PfaA compensates for loss of FabD activity. Heterologous expression of either pfaABCD from P. profundum SS9 or pfaABCDE from Shewanella pealeana in Escherichia coli complemented the loss of the chromosomal copy of fabD in vivo. The co-occurrence of independent, yet compensatory, fatty acid biosynthetic pathways in selected marine bacteria may provide genetic redundancy to optimize fitness under extreme conditions. IMPORTANCE A defining trait among many cultured piezophilic and/or psychrophilic marine Gammaproteobacteria is the incorporation of both monounsaturated and polyunsaturated fatty acids into membrane phospholipids. The biosynthesis of these different classes of fatty acid molecules is linked to two genetically distinct co-occurring pathways that utilize the same pool of intracellular precursors. Using a genetic approach, new insights into the interactions between these two biosynthetic pathways have been gained. Specifically, core fatty acid biosynthesis genes previously thought to be essential were found to be nonessential in strains harboring both pathways due to functional overlap between the two pathways. These results provide new routes to genetically optimize long-chain omega-3 polyunsaturated fatty acid biosynthesis in bacteria and reveal a possible ecological role for maintaining multiple pathways for lipid synthesis in a single bacterium.
- Published
- 2021
32. Does the magnitude of injuries affect the outcome of proximal humerus fractures treated by locked plating (PHILOS)?
- Author
-
Berk, Till, Halvachizadeh, Sascha, Bellmann, Frederik, Büsser, Lucas, Pape, Hans-Christoph, and Allemann, Florin
- Published
- 2022
- Full Text
- View/download PDF
33. Proximal humerus fractures (PHFs): comparison of functional outcome 1 year after minimally invasive plate osteosynthesis (MIPO) versus open reduction internal fixation (ORIF)
- Author
-
Buchmann, Laura, van Lieshout, Esther M. M., Zeelenberg, Miliaan, den Hartog, Dennis, Pfeifer, Roman, Allemann, Florin, Pape, Hans-Christoph, and Halvachizadeh, Sascha
- Published
- 2022
- Full Text
- View/download PDF
34. A retrospective comparison of clinical and radiological outcomes using palmar or dorsal plating to treat complex intraarticular distal radius fractures (AO 2R3 C3)
- Author
-
Child, Christopher, Müller, Annika, Allemann, Florin, Pape, Hans-Christoph, Welter, JoEllen, Breiding, Philipe, and Hess, Florian
- Published
- 2022
- Full Text
- View/download PDF
35. Equilibria of plane convex bodies
- Author
-
Allemann, Jonas, Hungerbühler, Norbert, and Wasem, Micha
- Subjects
Mathematics - Differential Geometry ,Mathematics - Classical Analysis and ODEs ,52A10, 54C30, 53A04 - Abstract
We obtain a formula for the number of horizontal equilibria of a planar convex body $K$ with respect to a center of mass $O$ in terms of the winding number of the evolute of $\partial K$ with respect to $O$. The formula extends to the case where $O$ lies on the evolute of $\partial K$ and a suitably modified version holds true for non-horizontal equilibria., Comment: 21 pages, 8 figures
- Published
- 2019
- Full Text
- View/download PDF
36. Genetic regulation of the bacterial omega-3 polyunsaturated fatty acid biosynthesis pathway.
- Author
-
Allemann, Marco N and Allen, Eric E
- Subjects
Nutrition ,Complementary and Integrative Health ,Prevention ,Genetics ,regulation ,polyunsaturated fatty acid ,fatty acids ,deep-sea bacteria ,Biological Sciences ,Agricultural and Veterinary Sciences ,Medical and Health Sciences ,Microbiology - Abstract
A characteristic among many marine Gammaproteobacteria is the biosynthesis and incorporation of omega-3 polyunsaturated fatty acids into membrane phospholipids. The biosynthesis of eicosapentaenoic (EPA) and/or docosahexaenoic (DHA) acids is mediated by a polyketide/fatty acid synthase mechanism encoded by a set of five genes, pfaABCDE. This unique fatty acid synthesis pathway co-exists with the principal type II dissociated fatty acid synthesis pathway, which is responsible for the biosynthesis of core saturated, monounsaturated, and hydroxylated fatty acids used in phospholipid and lipid A biosynthesis. In this work, a genetic approach was undertaken to elucidate genetic regulation of the pfa genes in the model marine bacterium Photobacterium profundum SS9. Using a reporter gene fusion, we showed that expression of the pfa operon is down regulated in response to exogenous fatty acids, particularly long chain monounsaturated fatty acids. This regulation occurs independently of the canonical fatty acid regulators, FabR and FadR, present in P. profundum SS9. Transposon mutagenesis and screening of a library of mutants identified a novel transcriptional regulator, which we have designated pfaF, to be responsible for the observed regulation of the pfa operon in P. profundum SS9. Gel mobility shift and DNase I footprinting assays confirmed that PfaF binds the pfaA promoter and identified the PfaF binding site.Importance The production of long-chain omega-3 polyunsaturated fatty acids (PUFA) by marine Gammaproteobacteria, particularly those from deep-sea environments, has been known for decades. These unique fatty acids are produced by a polyketide-type mechanism and subsequently incorporated into the phospholipid membrane. While much research has focused on the biosynthesis genes, their products and the phylogenetic distribution of these gene clusters, no prior studies have detailed the genetic regulation of this pathway. This study describes how this pathway is regulated under various culture conditions and has identified and characterized a fatty acid responsive transcriptional regulator specific to PUFA biosynthesis.
- Published
- 2020
37. Changes in Attentional Function in Patients From Before Through 12 Months After Breast Cancer Surgery.
- Author
-
Kohler, Carmen, Chang, Ming, Allemann-Su, Yu-Yin, Vetter, Marcus, Jung, Miyeon, Jung, Misook, Conley, Yvette, Paul, Steven, Kober, Kord M, Cooper, Bruce A, Smoot, Betty, Levine, Jon D, Miaskowski, Christine, and Katapodi, Maria C
- Subjects
Humans ,Breast Neoplasms ,Fatigue ,Mastectomy ,Attention ,Female ,Sleep Wake Disorders ,Cancer-related cognitive impairment ,anxiety ,attentional function ,breast cancer ,coping ,fatigue ,sleep disturbance ,Cancer ,Behavioral and Social Science ,Clinical Research ,Breast Cancer ,Medical and Health Sciences ,Anesthesiology - Abstract
ContextAlthough approximately 75% of patients with breast cancer report changes in attentional function, little is known about how demographic, clinical, symptom, and psychosocial adjustment (e.g., coping) characteristics influence changes in the trajectories of attentional function over time.ObjectivesThis study evaluated interindividual variability in the trajectories of self-reported attentional function and determined which demographic, clinical, symptom, and psychosocial adjustment characteristics were associated with initial levels and with changes in attentional function from before through 12 months after breast cancer surgery.MethodsBefore surgery, 396 women were enrolled. Attentional Function Index (AFI) was completed before and nine times within the first 12 months after surgery. Hierarchical linear modeling was used to determine which characteristics were associated with initial levels and trajectories of attentional function.ResultsGiven an estimated preoperative AFI score of 6.53, for each additional month, the estimated linear rate of change in AFI score was an increase of 0.054 (P
- Published
- 2020
38. Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database
- Author
-
Wittwer NL, Meier CR, Huber CA, Meyer zu Schwabedissen HE, Allemann S, and Schneider C
- Subjects
pgx ,drug use ,claims data ,pharmacoepidemiology ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Nina L Wittwer,1,2 Christoph R Meier,1– 3 Carola A Huber,4 Henriette E Meyer zu Schwabedissen,1 Samuel Allemann,1,* Cornelia Schneider1,2,* 1Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; 2Hospital Pharmacy, University Hospital Basel, Basel, Switzerland; 3Boston Collaborative Drug Surveillance Program, Lexington, MA, USA; 4Department of Health Sciences, Helsana Insurance Group, Zürich, Switzerland*These authors contributed equally to this workCorrespondence: Samuel Allemann, Pharmaceutical Care Research Group University of Basel, Department of Pharmaceutical Sciences, Klingelbergstrasse 50, Basel, 4056, Switzerland, Tel +41 61 207 61 76, Email s.allemann@unibas.chPurpose: In Switzerland 167 drugs on the market contain information about pharmacogenetics in their drug label (PGx drug). Preemptive pharmacogenetic testing is reimbursed by health care insurance for only seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) although, it is proposed to be a cost-effective approach to personalized medicine. The aim of this study was to describe the use of PGx drugs and their corresponding genes in Switzerland.Methods: We identified 90 drugs with dosing recommendations from the Pharmacogenetic Knowledgebase involving 24 genes. We assessed the utilization of those drugs between 2016 and 2020, using claims data from a large Swiss insurance company (Helsana).Results: Of 841 491 persons with drug claims during the whole study period, 78.7% were exposed to PGx drugs. Ibuprofen, pantoprazole, and tramadol had the highest number of users. Seven genes (CYP2C19, CYP2C9, CYP2D6, SLCO1B1, HLA-B, MT-RNR1, and VKORC1) were responsible for over 95% of all potential drug-gene interactions.Conclusion: The prevalence of PGx drug prescriptions is high in the Swiss population. Therefore, intensified preemptive testing may be a useful option as a substantial amount of the Swiss population might benefit.Keywords: PGx, drug use, claims data, pharmacoepidemiology
- Published
- 2022
39. Education in Flow Chemistry
- Author
-
Christophe Allemann and Roger Marti
- Subjects
Continuous process ,Education ,Flow chemistry ,Process intensification ,Chemistry ,QD1-999 - Abstract
Flow chemistry is a growing and promising technology that can be used in research, development, and production. Nowadays, properly trained staff in flow chemistry is lacking in industry. To efficiently work with this technology, a mix of engineering and chemical skills is required. Although, this dual education is well addressed in the chemistry major given at the Haute Ecole d’Ingénierie et d’Architecture de Fribourg, a school of the University of Applied Sciences and Arts, Western Switzerland, the teaching in flow chemistry should be enhanced and reinforced.
- Published
- 2023
- Full Text
- View/download PDF
40. Author’s Reply: Drain Versus No Drain in Open Mesh Repair for Incisional Hernia, Results of a Prospective Randomized Controlled Trial
- Author
-
Allemann, Pierre, Willemin, Mélissa, Demartines, Nicolas, and Schäfer, Markus
- Published
- 2023
- Full Text
- View/download PDF
41. Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report
- Author
-
Jeiziner C, Allemann SS, Hersberger KE, and Meyer zu Schwabedissen HE
- Subjects
pharmacogenetics (pgx) ,abcb1 ,slc19a1 ,mthfr ,rheumatoid arthritis ,methotrexate (mtx) ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Chiara Jeiziner,1 Samuel S Allemann,1 Kurt E Hersberger,1 Henriette E Meyer zu Schwabedissen2 1Pharmaceutical Care Research Group, Department Pharmaceutical Sciences, University of Basel, Basel, Switzerland; 2Biopharmacy, Department Pharmaceutical Sciences, University of Basel, Basel, SwitzerlandCorrespondence: Chiara Jeiziner, Pharmaceutical Care Research Group, Department Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, Basel, 4056, Switzerland, Tel +41 61 207 61 80, Email chiara.jeiziner@unibas.chPurpose: Pharmacogenetic (PGx) panel testing could help to determine the heritable component of a rheumatoid arthritis (RA) patient’s susceptibility for therapy failure and/or adverse drug reactions (ADRs) from methotrexate (MTX). Considering the literature mentioning the potential applicability of PGx panel testing within MTX regimens, we discuss the case of a patient who was treated with MTX, suffered from ADRs, and obtained a reactive PGx panel testing.Genotyping: We used a commercial PGx panel test involving the ABC-transporters P-glycoprotein (P-gp; gene: ABCB1), and breast cancer resistance protein (BCRP; gene: ABCG2), the solute carriers reduced folate carrier 1 (RFC1; gene: SLC19A1), and organic anion transporting polypeptide 1B1 (OATP1B1; gene: SLCO1B1), and the enzymes inosine triphosphatase (ITPA), and glutathione transferase P1 (GSTP1). In addition, we genotyped the patient for the enzymes 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICAR)/inosine monophosphate (IMP) cyclohydrolase (gene name: ATIC), gamma-glutamyl hydrolase (gene name: GGH) and methylenetetrahydrofolate reductase (gene name: MTHFR).Results: The PGx profile of the patient revealed genetic variants in SLC19A1, ABCB1, and MTHFR, which may explain the ADRs experienced during the treatment with MTX and a potentially lower efficacy of MTX. Based on our interpretation of the PGx profile, we recommended the patient to avoid MTX in the future.Conclusion: The MTX pathway is complex, which makes the interpretation of genetic variants affecting metabolism challenging. A reactive PGx panel test was applicable to explain ADRs experienced during MTX treatment for a patient with RA. However, the clinical utility of PGx-guided MTX treatment in a primary care setting is still limited. In order to base a recommendation for MTX on PGx data, we need genome-wide association studies, large prospective multicenter studies and PGx studies, which analyze different multi-gene haplotypes and gene-drug-drug interactions for MTX.Keywords: pharmacogenetics, PGx, ABCB1, SLC19A1, MTHFR, rheumatoid arthritis, methotrexate, MTX
- Published
- 2022
42. Development and acceptance of a new adherence monitoring package to identify non-adherent patients with polypharmacy in primary care: a feasibility study
- Author
-
Andreas Zeller, Samuel Allemann, Isabelle Arnet, and Fine Dietrich
- Subjects
Medicine (General) ,R5-920 - Abstract
Background Adherence to pharmacotherapy is crucial to prevent symptom deterioration in chronic diseases. However, non-adherence to chronic treatments is prevalent, especially in polypharmacy. Practical tools to assess adherence to polypharmacy in primary care are missing.Aims We aimed to develop an Adherence Monitoring Package (AMoPac) for general practitioners (GPs) to identify patient non-adherence. We tested the feasibility and acceptance of AMoPac in the primary healthcare setting.Methods AMoPac was developed based on peer-reviewed literature. It consists in (1) electronic monitoring of patients’ medication intakes for 4 weeks, (2) receiving feedback on intake behaviour by the pharmacist and (3) generating an adherence report to communicate to the GPs. A feasibility study was conducted with heart failure patients. GPs’ acceptance of AMoPac was explored with semistructured interviews. Electronic transmission of the reports into the GP’s electronic health record along with laboratory reports stating N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels was analysed.Results We developed AMoPac and tested its feasibility with six GPs and seven heart failure patients. GPs were satisfied with the adherence report including the pharmaceutical-clinical recommendations. Integrated transmission of adherence reports to GPs was not feasible due to technical incompatibilities. Mean taking adherence was 86.4%±12.8% and three patients had low correct dosing-days (69%, 38% and 36%, respectively). NT-proBNP ranged from 102 to 8561 pg/mL and four patients had elevated values (>1000 pg/mL).Conclusion AMoPac is feasible in the primary healthcare setting, excluding the integrated transmission of adherence reports to GPs. The procedure was highly accepted by GPs and patients. AMoPac fills a gap by combining clinical values with adherence data, and therefore, delivers a multifaceted picture of the patient’s behaviour. In case of unmet adherence, our tool might facilitate the selection of patient-centred approaches to optimise pharmacological therapies in chronic heart failure patients.Trial registration number NCT04326101.
- Published
- 2023
- Full Text
- View/download PDF
43. Algorithm-aided engineering of aliphatic halogenase WelO5* for the asymmetric late-stage functionalization of soraphens
- Author
-
Büchler, Johannes, Malca, Sumire Honda, Patsch, David, Voss, Moritz, Turner, Nicholas J., Bornscheuer, Uwe T., Allemann, Oliver, Le Chapelain, Camille, Lumbroso, Alexandre, Loiseleur, Olivier, and Buller, Rebecca
- Published
- 2022
- Full Text
- View/download PDF
44. Algorithm-aided engineering of aliphatic halogenase WelO5* for the asymmetric late-stage functionalization of soraphens
- Author
-
Johannes Büchler, Sumire Honda Malca, David Patsch, Moritz Voss, Nicholas J. Turner, Uwe T. Bornscheuer, Oliver Allemann, Camille Le Chapelain, Alexandre Lumbroso, Olivier Loiseleur, and Rebecca Buller
- Subjects
Science - Abstract
The late-stage functionalization of unactivated carbon–hydrogen bonds is a difficult but important task, which has been met with promising but limited success through synthetic organic chemistry. Here the authors use machine learning to engineer WelO5* halogenase variants, which led to regioselective chlorination of inert C–H bonds on a representative polyketide that is a non-natural substrate for the enzyme.
- Published
- 2022
- Full Text
- View/download PDF
45. Swept-source optical coherence tomography detects anterior-chamber changes in patients with angle-closure after laser peripheral iridotomy.
- Author
-
Esporcatte, Bruno L. B., Yanagimori, Norton S., Bufarah, Guilherme H., Vessani, Roberto M., Melo Jr., Luiz Alberto S., Allemann, Norma, and Tavares, Ivan Maynart
- Subjects
OPTICAL coherence tomography ,ANTERIOR chamber (Eye) ,ANTERIOR eye segment ,LASER therapy ,LASERS ,GONIOSCOPY ,IRIS (Eye) - Abstract
Copyright of Arquivos Brasileiros de Oftalmologia is the property of Arquivos Brasileiros de Oftalmologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
46. Simulation-Guided Engineering Enables a Functional Switch in Selinadiene Synthase toward Hydroxylation.
- Author
-
Srivastava, Prabhakar L., Johns, Sam T., Voice, Angus, Morley, Katharine, Escorcia, Andrés M., Miller, David J., Allemann, Rudolf K., and van der Kamp, Marc W.
- Published
- 2024
- Full Text
- View/download PDF
47. Using mini-arthrotomy for dorsal plating to treat intraarticular distal radius fractures: can it improve radiological and clinical outcomes?
- Author
-
Müller, Annika, Child, Christopher, Allemann, Florin, Pape, Hans-Christoph, Breiding, Philipe, and Hess, Florian
- Published
- 2021
- Full Text
- View/download PDF
48. Cost-Benefit Analysis of an Enhanced Recovery Program for Gastrectomy A Retrospective Controlled Analysis
- Author
-
Luzuy-Guarnero, Valentine, Gronnier, Caroline, Figuereido, Sergio, Mantziari, Styliani, Schäfer, Markus, Demartines, Nicolas, and Allemann, Pierre
- Published
- 2021
- Full Text
- View/download PDF
49. Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial
- Author
-
Céline K. Stäuble, Markus L. Lampert, Samuel Allemann, Martin Hatzinger, Kurt E. Hersberger, Henriette E. Meyer zu Schwabedissen, Christian Imboden, and Thorsten Mikoteit
- Subjects
Pharmacogenomics ,Depression ,Antidepressant ,Pharmaceutical care ,Psychiatry ,Medicine (General) ,R5-920 - Abstract
Abstract Background It is known that only 50% of patients diagnosed with major depressive disorders (MDD) respond to the first-line antidepressant treatment. Accordingly, there is a need to improve response rates to reduce healthcare costs and patient suffering. One approach to increase rates of treatment response might be the integration of pharmacogenetic (PGx) testing to stratify antidepressant drug selection. The goal of PGx assessments is to identify patients who have an increased risk to experience adverse drug reactions or non-response to specific drugs. Especially for antidepressants, there is compiling evidence on PGx influencing drug exposure as well as response. Methods This study is an open-label, randomized controlled trial conducted in two study centers in Switzerland: (1) the Psychiatric Clinic of Solothurn and (2) the Private Clinic Wyss in Münchenbuchsee. Adult inpatients diagnosed with a unipolar moderate or severe depressive episode are recruited at clinic admission and are included in the study. If the adjustment to a new antidepressant pharmacotherapy is necessary, the participants are randomized to either Arm A (intervention group) or Arm B (control group). If no new antidepressant pharmacotherapy is introduced the participants will be followed up in an observational arm. The intervention is the service of pharmacist-guided pre-emptive PGx testing to support clinical decision making on antidepressant selection and dosing. As a comparison, in the control group, the antidepressant pharmacotherapy is selected by the treating physician according to current treatment guidelines (standard of care) without the knowledge of PGx test results and support of clinical pharmacists. The primary outcome of this study compares the response rates under antidepressant treatment after 4 weeks between intervention and control arm. Discussion The findings from this clinical trial are expected to have a direct impact on inter-professional collaborations for the handling and use of PGx data in psychiatric practice. Trial registration ClinicalTrials.gov NCT04507555 . Registered on August 11, 2020. Swiss National Clinical Trials Portal SNCTP000004015 . Registered August 18, 2020.
- Published
- 2021
- Full Text
- View/download PDF
50. Complexation Behavior of Pinene–Bipyridine Ligands towards Lanthanides: The Influence of the Carboxylic Arm
- Author
-
Atena B. Solea, Liangru Yang, Aurelien Crochet, Katharina M. Fromm, Christophe Allemann, and Olimpia Mamula
- Subjects
pinene–bipyridine ligands ,lanthanide complexes ,association constants ,UV-Vis spectroscopy ,self-assembly ,supramolecular chemistry ,Chemistry ,QD1-999 - Abstract
The complexation behavior of two novel, chiral pinene–bipyridine-type ligands ((–)-HL1 and (–)-HL2) containing a carboxylic arm towards lanthanide Ln(III) (Ln = La, Eu, Lu) ions was investigated through spectroscopic methods. The association constants of the mononuclear complexes determined from the UV-Vis titrations indicated that the ligand (–)-HL1 possessing a shorter carboxylic arm formed more stable complexes compared with (–)-HL2, whose carboxylic arm had one more methylene unit. This is due to the formation of more stable seven-member metal chelate rings in the first case as compared with the eight-member metal chelate rings in the second. IR and fluorescence spectroscopy provided additional information about the structure of these complexes.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.